01. Doctor Overview

Doctor Overview

Dr. Steven Ades is a medical oncologist at the the University of Vermont Medical Center and associate professor at the Larner College of Medicine at UVM in Burlington, Vermont. Dr. Ades has expertise inperitoneal mesothelioma, with a particular interest in放射治疗for abdominal mesothelioma and supportive care for patients.

Dr. Ades has been involved in clinical research focusing on adjuvant therapies inmultimodal treatmentplans to improve patient outcomes. He has also helped research生物标志物，这可能允许较早的检测和诊断许多癌症，包括间皮瘤。万博专业版Ades博士已撰写并共同撰写40多篇文章和医学研究，这些研究可以在如此临床肿瘤学杂志。

02. Fast Facts

Doctor Fast Facts

主要特色：Medical Oncology

其他兴趣和特色：Mesothelioma and peritoneal mesothelioma, adrenal cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, carcinoid tumor, carcinoma, colon cancer, esophageal cancer, gallbladder cancer, gastrointestinal cancer, genitourinary cancer, hematologic cancer, kidney cancer, liver cancer, neuroendocrine cancer, Non-Hodgkin’s lymphoma, oncology, pancreatic cancer, penile cancer, prostate cancer, rectal cancer, small intestine cancer, stomach cancer, testicular cancer and urethral cancer.

Certifications, Awards & Accolades:Board Member of the American Board of Internal Medicine for Internal Medicine and Board Member of American Board of Internal Medicine for Medical Oncology

教育与经验：

• Graduate of McGill University
• Fellowship for Oncology at New England Medical Center Hospitals
• 金斯敦综合医院内科居住
• 麦吉尔大学医学院的医学学位

03. Publications

Publications

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial。临床肿瘤学杂志。May 2018;36:15.

NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors。生物标志物研究。April 2018;6:15. doi:10.1186/s40364-018-0129-8

增强Khorana评分：传统的vteb风险因素在预测发起化疗的癌症患者的长期vteb风险方面是重要的。Blood。2017年;130：753。